Loading
institutionsInstitution
Lustgarten Foundation
The largest private funder of pancreatic cancer research, which funds dedicated laboratories at Cold Spring Harbor, Johns Hopkins, Dana-Farber and MIT.
Also called: Lustgarten Foundation for Pancreatic Cancer Research
Overview
Founded in 1998 in memory of Cablevision executive Marc Lustgarten, the foundation devotes all donations to pancreatic cancer research, with administrative costs underwritten by Cablevision and later Altice. It funds Lustgarten Laboratories, including the Lustgarten Foundation Pancreatic Cancer Research Laboratory at Cold Spring Harbor led by David Tuveson, dedicated labs at Johns Hopkins (Vogelstein and Kinzler, early detection), Dana-Farber and MIT, and it co-sponsors the Stand Up To Cancer-Lustgarten Pancreatic Cancer Dream Teams. Its Clinical Accelerator Initiative funds early trials of new agents and its Pancreatic Cancer Collective with SU2C funds computational and interception projects.
Location
Woodbury, NY, US
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#377 · 16 points (0 Newsweek + 0 NCI + 16 from 8 linked objects) · ranking
- Lustgarten Laboratories (CSHL, Johns Hopkins, Dana-Farber, MIT)
- SU2C-Lustgarten Dream Teams and Pancreatic Cancer Collective
- Clinical Accelerator Initiative
- Early detection research
Linda Tantawi
Chief Executive Officer
Non-profit leadershipPancreatic cancer research funding
Chief Executive Officer of the Lustgarten Foundation, the largest private funder of pancreatic cancer research.
Marc Lustgarten
Cablevision executive whose pancreatic cancer diagnosis launched the Lustgarten Foundation
Pancreatic cancer research fundingPatient-founded foundations
Diagnosed with pancreatic cancer in 1998 at 51, he set up a foundation that awarded ten $100,000 grants in its first year and became the largest private funder of pancreatic cancer research; he died in 1999.
David A. Tuveson
Director, CSHL Cancer Center; Roy J. Zuckerberg Professor
Pancreatic cancerOrganoidsTumour stroma
Built the pancreatic cancer organoid models now used to test drugs against a patient's own tumour.
Bert Vogelstein
Clayton Professor of Oncology; Co-Director, Ludwig Center; HHMI Investigator
Cancer geneticsColorectal tumorigenesisLiquid biopsy
Bert Vogelstein is the most-cited scientist in cancer genetics: he mapped how colorectal cancer develops and founded the field of cancer genome sequencing and blood-based detection.
Kenneth W. Kinzler
Professor of Oncology; Co-Director, Ludwig Center
Cancer geneticsAPC and Wnt signallingGenome sequencing
Co-discovered APC, the gatekeeper gene of colorectal cancer, and co-led the first cancer genome sequences.
Andrew J. Aguirre
Institute Member, Broad; Physician, Dana-Farber
Pancreatic cancerKRAS biologyOrganoids
Uses organoids and functional genomics to find what pancreatic cancers depend on beyond KRAS.
Eileen M. O'Reilly
Winthrop Rockefeller Chair in Medical Oncology; Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
Pancreatic cancerBiliary cancerBRCA-associated pancreatic cancer
Leading pancreatic cancer trialist, including the maintenance PARP-inhibitor and germline-BRCA studies.
Similar pages
- Key paperDETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms
Shares Kenneth W. Kinzler, Bert Vogelstein, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, The hardest cancers are found late.
- Key paperDetection and localization of surgically resectable cancers with a multi-analyte blood test
Shares Kenneth W. Kinzler, Bert Vogelstein, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Liquid biopsy (ctDNA).
- Key paperReal-time genomic characterization of advanced pancreatic cancer to enable precision medicine
Shares Andrew J. Aguirre, David A. Tuveson, Dana-Farber Brigham Cancer Center, Pancreatic ductal adenocarcinoma.
- Key paperDistinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Shares David A. Tuveson, Cold Spring Harbor Laboratory, Patient-derived organoids, Pancreatic ductal adenocarcinoma.
- Key paperDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Shares Kenneth W. Kinzler, Bert Vogelstein, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Pancreatic ductal adenocarcinoma.
- Key paperWhole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways
Shares Kenneth W. Kinzler, Bert Vogelstein, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Pancreatic ductal adenocarcinoma.
- Key paperThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Shares Kenneth W. Kinzler, Bert Vogelstein, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Liquid biopsy (ctDNA).
- Key paperGenetic instability in colorectal cancers
Shares Kenneth W. Kinzler, Bert Vogelstein, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center.